Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis

Study HZA106851: A Study of the Effects of Inhaled Fluticasone Furoate/GW642444 Versus Placebo on the HPA Axis of Adolescent and Adult Asthmatics

The purpose of this study is to assess the effect of six weeks' treatment with two once-daily strengths of Fluticasone Furoate/GW642444 Inhalation Powder on the HPA axis system

Inclusion Criteria:

• Outpatient with ability to comply with study requirements and complete two 24-hour clinic visits
• Clinical diagnosis of asthma for greater than/equal to 12 weeks
• Reversibility FEV1 of at least twelve percent and two hundred milliliters
• FEV1 greater than or equal to fifty percent of predicted

Exclusion Criteria:

• History of life threatening asthma
• Respiratory infection or oral candidiasis
• Asthma exacerbation
• Uncontrolled disease or clinical abnormality
• Allergies to study drugs, study drugs' excipients, medications related to study drugs
• Taking another investigational medication or prohibited medication